CCM
RVNC

Cadence Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cadence Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-54,524
Closed -$1.33M – 402
2020
Q2 		$1.33M Buy
+54,524
New +$1.08M 0.19% 165

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Cadence Capital Management's RVNC Position: Q3 2020 in Review

Cadence Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2020, closing a stake of 54,524 shares — an estimated $1.33M sold.

Cadence Capital Management first reported a position in RVNC in Q2 2020 and held it in 1 quarter. The position peaked at $1.33M in Q2 2020. 153 funds tracked by Wall St. Rank hold RVNC as of Q3 2020.

  • Cadence Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Cadence Capital Management sold 54,524 Revance Therapeutics, Inc. shares in Q3 2020, an estimated $1.33M.
  • Cadence Capital Management first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • Cadence Capital Management's Revance Therapeutics, Inc. position peaked at $1.33M in Q2 2020.
  • 153 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.